(Q38219591)

31 August 2017

title

Ustekinumab: a review of its use in psoriatic arthritis (English)

1 reference

31 August 2017

1

Kate McKeage

1 reference

31 August 2017

publication date

1 June 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

74

1 reference

31 August 2017

issue

9

1 reference

31 August 2017

page(s)

1029-1039

1 reference

Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Ustekinumab for psoriasis and psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Ustekinumab : targeting the IL-17 pathway to improve outcomes in psoriatic arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: a randomized, placebo-controlled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Long-term safety of ustekinumab for psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0242-4

Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up

21 January 2018

1 reference

12 December 2020

Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use

1 reference

12 December 2020

Diagnosing and treating psoriatic arthritis: an update

1 reference

12 December 2020

Population pharmacokinetics of ustekinumab in patients with active psoriatic arthritis

1 reference

12 December 2020

A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis

1 reference

12 December 2020

Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis

1 reference

12 December 2020

An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up

1 reference

12 December 2020

10.1007/S40265-014-0242-4

Identifiers

DOI

1 reference

Dimensions Publication ID

31 August 2017

1036946575

0 references

1 reference